CD274 and gastric cancer: Results from the multinational, double-blind, randomized phase 3 trial MATTERHORN, confirmed the benefits of PD-L1 blockade via durvalumab in addition to perioperative chemotherapy in gastric cancer (GC) and cancer of the gastroesophageal junction (GEJ).1